

Table 1. Baseline characteristics of patients with acromegaly treated with somatostatin analogs (SSA)

	SSA before surgery N = 11	SSA after surgery N = 62	p
Age at diagnosis (median, range) (years)	42.00 [21 – 62]	40.50 [21 – 68]	NS
Sex	4 M : 7 F	22 M : 40 F	NS
Previous radiotherapy, n (%)	1 (9.09)	41 (66.12)	0.001
SSA treatment duration (median, range) (months)	9.00 [3 – 17]	15.00 [3 – 44]	0.007
Tumor size at diagnosis (n)	10 macro, 1 micro (<1 cm)	57 macro, 4 micro, 1 unknown	NS
Tumor size before SSA (n)	9 macro, 2 micro	42 macro, 20 micro	NS
Tumor area at diagnosis (median, range) (cm ²)	3.41 [0.51-9.97] (n = 9)	1.89 [0.5-13.06] (n = 58)	NS
Tumor area before SSA (median, range) (cm ²)	3.43 [0.51-9.97]	0.64 [0.5-9.80]	<0.05
Invasive tumor, n (%)	5 (45.4)	21 (33.8)	NS
Random serum GH before SSA (median, range) (μg/L)	25.10 [4.35-176]	6.80 [1.2-162]	0.09
Serum IGF-1 before SSA, × ULN (median, range)	3.56 [2.30-7.40]	2.20 [0.5-9.40]	<0.05
Treatment	LAN-SR: 1 OCT-LAR: 10	LAN-SR: 36 OCT-LAR: 26 Both consecutively: 9	

Legend: ULN = IGF-1 upper limit of normal range for age, macro -macroadenoma, micro -microadenoma